Dr. Anthony Letai led a study showing a new technique that can predict which specific drug will be most effective in treating various types of cancer tumors.
Dr. Lawrence Shulman wrote about his work in Rwanda and providing access to life-saving advances in cancer treatment through the collaborations of the Rwandan Ministry of Health, Partners in Health, and Dana-Farber.
Dr. James Bradner and his team continue to work on the JQ1 molecule, which tricks the body into forgetting how to make sperm.
Dr. Philip Kantoff commented on therapeutic cancer vaccines.
Dana-Farber was mentioned in a story about how bureaucracy and outdated rules often block potential breakthroughs, but precision medicine is providing hope.
Tags: BasicResearch, Genomics, Genetics
Dana-Farber plans to expand precision medicine research by moving some staff into the new Longwood Center. Several research programs will now be under one roof.
Tags: BasicResearch, Genomics
Dana-Farber was mentioned as one of the institutions affiliated with Harvard that benefited from research dollars from the National Institute of Health.
Dr. Edward J. Benz, Jr., talked about research to develop treatments for cancer that are more efficient and less toxic, by specifically targeting tumors using genetic analysis.
Tags: BasicResearch, TargetedTherapy
Cigall Kodach, PhD, spoke about the problems in today’s biology and medicine research on a panel at the Forbes Under 30 Summit.
Dana-Farber patient Grace Silva served as a case study of an “exceptional responder” for a treatment she underwent at the recommendation of her oncologists, Dr. Jochen Lorch and Dr. Nikhil Wagle.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: